| Status | Available to order |
| EMMA ID | EM:07003 |
| International strain name | STOCK Rag2tm1Fwa Ifnar1tm Tg(TcrLCMV)327Sdz/Orl |
| Alternative name | P14TCR-TG/Rag2-/-/InfaR-/- mice |
| Strain type | Targeted Mutant Strains : Knock-out |
| Allele/Transgene symbol | Ifnar1tm, Rag2tm1Fwa |
| Gene/Transgene symbol | Ifnar1, Rag2, Tg(TcrLCMV)327Sdz |
| Provider | Benedita Rocha |
| Provider affiliation | INSERM U 1020, INSERM |
| Additional owner | I am the exclusive owner of this crossing, but not of the individual strains used for the crossing that are generally available without restrictions. |
| Genetic information | This strain was generated by crossing the P14 transgenic mice, which bear a TCR transgene specific for the GP33-peptide of the Leukocyte Choriomeningitis Virus (LCMV), with two deficient mouse strains. The first was deficient in the recombinase Rag2 and the second in the receptor for the interferon alpha (Ifnar1, prev. InfaR). The resulting strain allows the study of the influence of interferon alpha (which is produced in very high amounts during LCMV infection) in the response of CD8 T cells to LCMV. We would cryopreserve this crossing since the fixation in the same mouse strain of 2 targeted mutations and one transgene was very difficult and we believe it will be of major interest to the immunology community. |
| Phenotypic information | Mice will have a single population of lymphocytes, those expressing the TCR transgene. |
| Breeding history | Currently bred homozygous for the Rag2 mutation and the TCR transgene, heterozygous for the Ifnar1 (InfarR) mutation. |
| References | None available |
| Homozygous fertile | no |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | yes |
| Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
| Animals used for archiving | homozygous C57BL/6J, wild-type C57BL/6J |
| Breeding at archiving centre | Males knock-out for Rag2 and Ifnar1 (InfaR), homozygous transgenic for Tg(TcrLCMV)327Sdz (P14TCR). Females heterozygous or wild-type for each mutation. |
| Stage of embryos | 2-cell |
Orphanet associated rare diseases, based on orthologous gene matching
